Alcon: Needham reiterates Buy with PT raised to $107 from $90.

Alcon: Needham reiterates Buy with PT raised to $107 from $90.

Alcon Inc. (NYSE: ALC) has received a continued 'Buy' rating from Needham with a price target raised to $107 from $90. The analyst, David Saxon, reiterated the recommendation, aligning with the previous ratings. This indicates continued confidence in Alcon's vision care portfolio and strategic direction.

Alcon is a leading vision care company with a diverse range of products, including contact lenses, lens care solutions, and surgical products. The company's latest acquisition of STAAR Surgical, a maker of implantable lenses, aims to strengthen its position in the refractive surgery market. This strategic move complements Alcon's existing laser vision correction portfolio, providing a more comprehensive range of surgical solutions for patients seeking alternatives to glasses or contact lenses.

The acquisition of STAAR Surgical, valued at approximately $1.5 billion, is expected to close within six to twelve months, subject to shareholder approval. The deal involves purchasing all outstanding shares of STAAR for $28 each in cash. This acquisition is aimed at leveraging STAAR's Collamer lenses, which are used to correct severe myopia and other vision problems without the need for corneal tissue removal.

Alcon's recent financial performance has been robust, with the company reporting quarterly revenue of $2.47 billion and a net profit of $350 million for the quarter ending March 31, 2025. These figures underscore Alcon's strong market position and growth potential in the eye care sector.

The continued 'Buy' rating from Needham reflects a positive outlook on Alcon's ability to capitalize on market opportunities and integrate STAAR's technology into its existing portfolio. Investors and financial professionals can expect Alcon to continue its expansion in the vision care market, driven by technological advancements and strategic acquisitions.

References:
[1] https://nz.finance.yahoo.com/quote/ALC.SW/
[2] https://techfundingnews.com/alcon-to-acquire-staar-surgical-in-1-5b-deal-for-vision-surgery-expansion/
[3] https://www.ainvest.com/news/kepler-capital-maintains-buy-rating-alcon-chf86-00-price-target-2508/
[4] https://www.ainvest.com/news/lensar-q2-earnings-revenue-10-merger-alcon-track-2025-close-2508/